Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Jun 30, 2023
Revenue increased for the quarter, driven by higher product sales. Both sequential and year-over-year comparisons showed growth.
Key takeaway
Quarter ended Jun 30, 2023 · FY2023 Q2
Revenue increased for the quarter, driven by higher product sales. Both sequential and year-over-year comparisons showed growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
+5.0%
Change from the immediately preceding quarter.
Year-over-year
+13.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2022 | $2.3B | +17.7% |
| Dec 31, 2022 | $2.3B | +11.1% |
| Mar 31, 2023 | $2.4B | +13.2% |
| Jun 30, 2023 | $2.5B | +13.5% |
Revenue performance
The reported revenue rose compared to the prior quarter and the same period last year.
Quarterly comparison
The quarter's revenue exceeded both the immediately preceding quarter and the year-ago quarter.
What to watch
Monitor the company's ability to sustain revenue growth amid competitive pressures.